Zali Pharmaceuticals: The development of Parkinson's pipeline LY-N001 by Lingyi Biotechnology is currently ongoing.

During the institutional research, Salix Pharmaceuticals stated that Lingyi Biological's Parkinson's pipeline LY-N001 is progressing steadily, with major pre-clinical research work already completed. This pipeline targets Parkinson's subtypes associated with GBA1 gene mutations, with the future goal of applying for IND in China and the US and conducting clinical research as well as expanding into the global market. Lingyi Biological is a company dedicated to the innovation of drugs for single gene genetic diseases, positioning itself as a developer of gene therapy drugs with differentiation advantages. In April 2025, Salix Pharmaceuticals increased its investment in Lingyi Biological by 20 million RMB.